Company Description
ALT5 Sigma Corporation, together with its subsidiaries, provides blockchain-powered technologies worldwide.
It operates through Fintech and Biotechnology segments. The company engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets.
Its products include ALT 5 Prime, an electronic over-the-counter trading platform for the buying and selling of digital assets; and ALT 5 Pay, a crypto-currency payment gateway that enables merchants to accept and make crypto currency payments or integrate the payment platform into their application.
The company is also involved identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies for the treatment of pain and addiction.
In addition, it develops JAN 101, an oral and sustained-release pharmaceutical composition of sodium nitrite that has completed Phase 2a clinical trial to treat peripheral arterial disease and pain; and JAN123, a formulation of low-dose naltrexone for the treatment of chronic regional pain syndrome.
The company was formerly known as JanOne Inc. and changed its name to ALT5 Sigma Corporation in July 2024.
ALT5 Sigma Corporation was founded in 1976 and is based in Las Vegas, Nevada.
| Country | United States |
| Founded | 1976 |
| Industry | Software - Application |
| Sector | Technology |
| Employees | 10 |
| CEO | Peter Tassiopoulos |
Contact Details
Address: 325 E. Warm Springs Road, Suite 102 Las Vegas, Nevada 89119 United States | |
| Phone | 702 997 5968 |
| Website | alt5sigma.com |
Stock Details
| Ticker Symbol | ALTS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000862861 |
| CUSIP Number | 74347B813 |
| ISIN Number | US47089W1045 |
| Employer ID | 41-1454591 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter Tassiopoulos | Chief Executive Officer and Director |
| Tony Isaac | President, Corporate Secretary, Treasurer and Chairman |
| Virland A. Johnson CPA | Chief Financial Officer |
| Dr. Tony Giordano Ph.D. | Chief Scientific Officer |
| Dr. Douglas Flanagan Ph.D. | Chief Formulation Advisor |
| Vay Tham | Chief Revenue Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 21, 2025 | 8-K | Current Report |
| May 14, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 28, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 10-K/A | [Amend] Annual report |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |